Brian Best Email & Phone Number

Greater Seattle Area

Providing strategic advisory services in a variety of healthcare-related fields, including precision medicine, clinical trial operations, and product commercialization in healthcare.

Seattle, Wa

CEO of Predigen, a Duke University spin out that is a global leader in the development of host gene expression signatures for use as prognostic, diagnostic, and therapeutic monitoring tools. Acquired by Biomeme, 2021.

Raleigh-Durham, North Carolina Area

Facilitated development of not-for-profit research organization devoted to improving the lives of children diagnosed with pediatric rheumatic diseases. Led team to secure > $40 million in capital to support implementation of numerous clinical and translational research programs.

Memphis, Tn

Founded company, managed licensing of drug-device intellectual property, facilitated USPTO filing to achieve patent issuance (2012 & 2014), developed business plan, raised seed capital (2012) and series A (2015) funding, and initiated strategic plan for development of drug eluting mesh for surgical repair of hernia, resulting in 510(k) FDA clearance in 2022.

San Francisco Bay Area

Providing consulting services to support small and large drug, device and diagnostic companies in commercial planning, product development, and strategy formulation. Developing and leading team of seasoned professionals to expand capabilities to western market.

Emeryville, Ca

Member of Management Team, responsible for developing Medical Affairs capability while creating and implementing strategic plan to define future of company and support additional venture capital investment.

Emeryville, Ca

Responsible for developing all commercial functions, including marketing, sales, and operations, for US launch of novel molecular diagnostic product in diabetes and cardiometabolic markets (primary care).

Winnipeg, Canada

Served as consultant to support sales, marketing, and medical affairs strategy for Medicure, post-failure of P3 study of MC-1. Provided strategic and tactical guidance for US marketing and worldwide deals relating to the commercialized product Aggrastat.

Winnipeg, Canada

Responsible for development of the sales/marketing/medical affairs organization, strategy, tactics, budget, and general commercial planning in support of the launch plan for the late stage cardioprotective agent MC-1, and the commercialized product Aggrastat. (MC-1 failed P3 trial in early 2008.)

San Francisco Bay Area

Provided consulting services for various biotech organizations seeking clinical and commercial expertise.- Strategic assessment of pipeline assets to determine optimal partnering/licensing strategy.- Market research to establish therapeutic landscape and customer segmentation.- Scenario planning to assess market evolution using scientific advisors and competitive intelligence.- Development of outcomes registry to inform clinical strategy.

San Francisco Bay Area

Employed as Consultant by the ACC to facilitate strategic planning for multiple national registry programs, including the acquisition of the NRMI registry from Genentech and the multi-sponsored CRUSADE registry to create the largest national cardiovascular database in the US. Registry work includes CARE (carotid revascularization registry), ACTION (ACS QI registry), Congenital registry, Imaging registry, and more.

San Francisco Bay Area

Responsible for hiring and managing Clinical Trial Liaison team to facilitate execution of phase 3 study, and for pre-launch commercial and clinical affairs planning, development, and activities.

Greater Boston Area

Led the Global Medical Affairs organization to optimize brand medical support and to develop Millennium’s first Medical Science Liaison (MSL) group.

Greater Boston Area

Resonsible for specialty/clinical sales organization and for executing sales and marketing collaboration with new European partner, GSK.

Greater Boston Area

Responsible for management of the INTEGRILIN brand ($400MM) and for managing the commercial partnership between Millennium and Schering.

Responsible for leading marketing activities for INTEGRILIN, and managed the development and implementation of new 67-person sales force.

Responsible for leading marketing activities for INTEGRILIN, and developed CRUSADE, the National Quality Improvement Initiative driving awareness and adoption of the ACC/AHA Guidelines, supported and coordinated by the Duke Clinical Research Institute (DCRI).

San Francisco Bay Area

Melbourne, Florida Area

Melbourne, Florida Area

Bs, Business

Biotechnology Management

Education program for biotechnology and pharmaceutical executives

Phamaceutical Marketing

Educational program for biotechnology and pharmaceutical executives